Roth MKM Sticks to Their Buy Rating for Insmed (INSM)

Roth MKM analyst Adam Walsh maintained a Buy rating on Insmed yesterday and set a price target of $212.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Walsh is a 3-star analyst with an average return of 6.0% and a 43.81% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Insmed, Arcturus Therapeutics, and vTv Therapeutics.

In addition to Roth MKM, Insmed also received a Buy from Goldman Sachs’s Andrea Newkirk in a report issued on February 11. However, on February 3, TipRanks – OpenAI reiterated a Hold rating on Insmed (NASDAQ: INSM).

Based on Insmed’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $142.34 million and a GAAP net loss of $370.02 million. In comparison, last year the company earned a revenue of $93.43 million and had a GAAP net loss of $220.52 million

Based on the recent corporate insider activity of 136 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year. Earlier this month, William Lewis, the Chair and CEO of INSM sold 3,009.00 shares for a total of $470,427.06.